DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

Relevant Financial Relationships

The following individuals involved in the planning, development, review, presentation, authoring and/or editing of the symposium content have disclosed relevant financial relationships with ineligible companies*, and the CME Department has mitigated these potential conflicts of interest. **Indicates that this individual's presentation will include discussion of off-label or unapproved usage.

- Ahluwalia, Manmeet, M.D., faculty for this educational activity, is a consultant with Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Caim Therapeutics, Theraguix, Anheart Therapeutics and Varian Medical Systems. He is also a researcher for AstraZeneca, Bayer, BMS, Incyte, Merck, Mimivax, Novocure and Pharmacyclics; is a shareholder with Mimivax, Cytodyn, MedInnovate Advisors LLC; and on the scientific advisory board for Cairn Therapeutics, Pyramid Biosciences and Modifi Biosciences. Dr. Ahluwalia indicated that the presentation or discussion will include off-label or unapproved product usage.
- Linfante, Italo, M.D.**, faculty for this activity is a consultant, advisor and owns royalties from Prolong Pharmaceuticals.
- McDermott, Michael, M.D., moderator for this activity is a consultant for Diende, Stryker, Insightech, Light Helmet, and OsteoMed.
- Odia, Yazmin, M.D.**, faculty for this activity has received grant/ research support from Bristol Myers Squibb, Novocure, Chimerix, Karyopharm, VBI Therapeutics, MIMIVAX, and CNS Pharmaceuticals. She is a consultant for Pharpoint Research and an advisor for Actuate Therapeutics, Oncoceutics Bod, DSMB Gamma Tile.
- Ouellete, Elizabeth Ann, M.D.**, faculty for this activity is an advisor for Integra.
- **Uribe, John M.D.**, faculty for this activity receives royalties from ConMed and owns stocks for Arthrosurface.
- Villa, Alessandro, DDS, Ph.D., MPH**, faculty for this activity has received grant/ research support from Mairagtx, Merck, Mureva. He is a consultant for Afyx Therapeutics, Lipella Pharmaceuticals and K Pharm. He receives royalties from UpToDate.

Nothing to Disclose

The following individual does not have relevant financial relationships with ineligible companies*.

**Indicates that this individual's presentation will include discussion of off-label or unapproved usage.

- Kalman, Noah, M.D.
- Kaiser, Adeel, M.D.
- Morcos, Marc, Ph.D.
- Lipkin, Scott, DPM
- Papagni, Paul J.D.
- Paraliticci, Giovanni, M.D.

*Ineligible companies are those whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.